NCT02554019 - Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 28, 2015

Primary Completion Date

October 25, 2017

Study Completion Date

October 25, 2017

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL

BT063

Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)

BIOLOGICAL

Placebo

Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)

Trial Locations (14)

Study Site 37505, Homyel

Study Site 37501, Minsk

Study Site 37502, Minsk

Study Site 37503, Minsk District

Study Site 37504, Vitebsk

Study Site 99501, Tbilisi

Study Site 99502, Tbilisi

Study Site 48003, Bialystok

Study Site 48004, Krakow

Study Site 48002, Poznan

Study Site 48001, Warsaw

Study Site 38101, Belgrade

Study Site 38103, Belgrade

Study Site 38102, Niška Banja